Abstract

This application seeks support for the activities of the National Clinical Trials Network (NCTN) as a Network Lead Academic Participating Site at the University of Wisconsin Carbone Cancer Center (UWCCC). For over 40 years, the UWCCC has maintained exemplary main institution accrual and strong affiliate participation while providing high quality data and key scientific leadership. The basic, translational, and clinical research programs of the UWCCC are designed to reduce the cancer burden on the population by improving prevention, early detection, and treatment of cancer. The UWCCC's commitment to cancer care and research has never been stronger and since 2002, an overall tripling of UWCCC clinical and research space has been implemented. The UWCCC faculty views the NCI cooperative groups as essential components in the war on cancer. Translation of scientific discovery to human populations and to individual patients requires an ability to conduct large scale clinical trials in a timely fashion. The NCTN provides this vital forum and the UWCCC remains highly committed and dedicated to this mutually beneficial partnership.

Public Health Relevance

NCTN clinical trials are a vitally important cancer treatment option for the citizens of Wisconsin. Group trials represent a proven system for improving outcomes for patients affected by cancer and the University of Wisconsin remains enthusiastic participants in the cooperative group system.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180799-03
Application #
9023508
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-22
Project End
2019-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
3
Fiscal Year
2016
Total Cost
$474,853
Indirect Cost
$159,336

  Institution

Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715

  Publications

Wagner, Lynne I; Zhao, Fengmin; Goss, Paul E et al. (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG Breast Cancer Res Treat 169:537-548
Scott, David W; King, Rebecca L; Staiger, Annette M et al. (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060-2064
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
Le-Petross, Huong T; McCall, Linda M; Hunt, Kelly K et al. (2018) Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol 210:669-676
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
King, Rebecca L; Nowakowski, Grzegorz S; Witzig, Thomas E et al. (2018) Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J 8:27
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121

Showing the most recent 10 out of 67 publications